• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

    11/26/25 8:48:00 AM ET
    $NVNO
    Medical/Dental Instruments
    Health Care
    Get the next $NVNO alert in real time by email

    Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, December 3rd at 4:00 PM ET

    IRVINE, CA / ACCESS Newswire / November 26, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Live Virtual Investor CEO Connect segment on Wednesday, December 3, 2025 at 4:00 PM ET.

    As part of the event, Mr. Berman will provide a corporate overview and discuss the Company's recent news and next steps. In addition to the moderated discussion, there will be a live question and answer session. Mr. Berman will answer as many questions as possible in the time allowed.

    A live video webcast of the presentation will be available on the Events page of the Company's website (www.envveno.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.

    About enVVeno Medical Corporation

    enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.

    Cautionary Note on Forward-Looking Statements

    This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

    ###

    INVESTOR CONTACT:

    Jenene Thomas, JTC Team, LLC
    [email protected]
    (908) 824-0775

    MEDIA CONTACT:
    Glenn Silver, FINN Partners
    [email protected]
    (973) 818-8198

    SOURCE: enVVeno Medical Corporation



    View the original press release on ACCESS Newswire

    Get the next $NVNO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVNO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVNO
    SEC Filings

    View All

    SEC Form S-8 filed by enVVeno Medical Corporation

    S-8 - enVVeno Medical Corp (0001661053) (Filer)

    3/26/26 4:38:54 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by enVVeno Medical Corporation

    10-K - enVVeno Medical Corp (0001661053) (Filer)

    3/26/26 4:24:27 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by enVVeno Medical Corporation

    SCHEDULE 13G/A - enVVeno Medical Corp (0001661053) (Subject)

    2/17/26 4:00:03 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    $NVNO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Duhay Francis sold $1,613 worth of shares (140 units at $11.52), decreasing direct ownership by 5% to 2,502 units (SEC Form 4)

    4 - enVVeno Medical Corp (0001661053) (Issuer)

    3/13/26 4:05:09 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Berman Robert Andrew

    4 - enVVeno Medical Corp (0001661053) (Issuer)

    12/18/25 6:24:02 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Technology Officer Alavi Hamed

    4 - enVVeno Medical Corp (0001661053) (Issuer)

    12/18/25 5:49:30 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    $NVNO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

    Successful Completion of All Planned Implants in GLP StudyenVVe Delivery System Demonstrates Consistent PerformanceCompany Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results IRVINE, CA / ACCESSWIRE / December 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful completion of the final wave of implants for shorter-term subjects in its six-month pre-clinical GLP study for enVVe, its transcatheter-delivered replacement venous valve. The successful completion of all planned implants in the GLP study, including both long-t

    12/16/24 8:50:00 AM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

    Interviews with participating patients from the VenoValve® U.S. Pivotal TrialWebcast replay from with the presenting Primary InvestigatorsPresentation with data from the VenoValve U.S. Pivotal TrialAccess the Recap Website Here!IRVINE, CA / ACCESSWIRE / November 27, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the launch of a recap website which highlights the Company's participation at the recently held 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium. Materials accessible on the recap website include interviews with two patients and

    11/27/24 8:30:00 AM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

    85% Clinical Meaningful Benefit Responder Rate7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort75% Median Reduction in Pain (VAS)87% Median Ulcer Area Reduction97% Target Vein Patency RateImprovement in All Patient Reported Quality-of-Life IndicatorsCompany to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st A

    11/20/24 8:30:00 AM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    $NVNO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Duhay Francis bought $249,999 worth of shares (81,433 units at $3.07), increasing direct ownership by 389% to 102,344 units (SEC Form 4)

    4 - enVVeno Medical Corp (0001661053) (Issuer)

    1/3/25 7:00:20 AM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    Director Gray Robert bought $10,290 worth of shares (3,500 units at $2.94), increasing direct ownership by 46% to 11,155 units (SEC Form 4)

    4 - enVVeno Medical Corp (0001661053) (Issuer)

    1/2/25 4:05:22 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    Director Shrivastava Sanjay bought $15,660 worth of shares (5,400 units at $2.90), increasing direct ownership by 139% to 9,288 units (SEC Form 4)

    4 - enVVeno Medical Corp (0001661053) (Issuer)

    12/26/24 4:30:21 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    $NVNO
    Leadership Updates

    Live Leadership Updates

    View All

    enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

    Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve®PMA application seeking FDA approval for the VenoValve on track to be filed in Q4 of 2024IRVINE, CA / ACCESSWIRE / April 9, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Andrew Cormack has been hired as the Company's Chief Commercial Officer. Mr. Cormack, who joined enVVeno Medical on April 8, comes to enVVeno following a career at both start-up and large medical device companies including WallabyPhenox, Medtronic, Covidien,

    4/9/24 8:45:00 AM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations

    IRVINE, CA / ACCESSWIRE / August 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the appointment of Kevin Belteau as Vice President of Clinical Operations. Mr. Belteau joins enVVeno Medical following a twenty-three-year career in clinical operations at Medtronic.Mr. Belteau joined Medtronic as a field engineer upon graduation from college and has progressed through various clinical operations roles over the course of his tenure there. Most recently he managed his own team of clinical operations professionals and has been directly involved is more than 75 clinical st

    8/16/22 8:05:00 AM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    $NVNO
    Financials

    Live finance-specific insights

    View All

    enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

    85% Clinical Meaningful Benefit Responder Rate7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort75% Median Reduction in Pain (VAS)87% Median Ulcer Area Reduction97% Target Vein Patency RateImprovement in All Patient Reported Quality-of-Life IndicatorsCompany to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st A

    11/20/24 8:30:00 AM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

    Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH SymposiumCompany to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20th at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 19, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it has submitted its application with the U.S. Food and Drug Administration (FDA) seeking approval to market and sell the VenoValve in the United States. Four (4) out of five (5) modules that comprise the VenoValve PMA application

    11/19/24 8:15:00 AM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    enVVeno Medical to Host Conference Call and Webcast on September 21, 2022

    - Conference call with live audio webcast to be held on Wednesday, September 21st at 4:30 PM ETIRVINE, CA / ACCESSWIRE / September 19, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it will host a conference call and webcast on Wednesday, September 21, 2022 at 4:30 PM ET.Interested participants and investors may access the conference call by dialing (877) 407-9708 (domestic) or (201) 689-8259 (international) and referencing conference ID: 13732870. The live webcast will be accessible on the Events page of the Investors section of the enVVeno website, envveno.com, and w

    9/19/22 8:05:00 AM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    $NVNO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by enVVeno Medical Corporation

    SC 13G/A - enVVeno Medical Corp (0001661053) (Subject)

    11/14/24 4:50:32 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by enVVeno Medical Corporation (Amendment)

    SC 13G/A - enVVeno Medical Corp (0001661053) (Subject)

    2/23/24 4:16:05 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by enVVeno Medical Corporation

    SC 13G - enVVeno Medical Corp (0001661053) (Subject)

    2/14/24 4:51:40 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care